Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Obsessive-Compulsive Disorder - Overview
Obsessive-Compulsive Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Obsessive-Compulsive Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
Amorsa Therapeutics Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Canbis Science Inc
Evecxia Therapeutics Inc
Octapharma AG
Omeros Corp
PharmaTher Holdings Ltd
Phytecs
Rugen Therapeutics R&D (Shanghai) Co Ltd
Obsessive-Compulsive Disorder - Drug Profiles
(betaine + ketamine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
CBISOCD-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EVX-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PECS-101 - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action
History of Events
rituximab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Target NMDA Receptor for Obsessive Compulsive Disorder - Drug Profile
Product Description
Mechanism Of Action
troriluzole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Obsessive-Compulsive Disorder - Dormant Projects
Obsessive-Compulsive Disorder - Discontinued Products
Obsessive-Compulsive Disorder - Product Development Milestones
Featured News & Press Releases
Aug 06, 2021: Chi NMPA approved the IND application for new glutamate modulator Troriluzole, siglling fresh hope for OCD patients
Jan 04, 2021: Biohaven begins pivotal Phase 3 trial of troriluzole in obsessive-compulsive disorder
Jun 24, 2020: Biohaven announces obsessive compulsive disorder (OCD) proof of concept phase 2/3 study results and program update
Sep 16, 2019: Omeros announces positive results from phase 1 study of its lead PDE7 inhibitor in development for addiction
Dec 21, 2017: Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
Oct 24, 2017: Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder
Jul 13, 2017: Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Obsessive-Compulsive Disorder, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, 2022
Obsessive-Compulsive Disorder - Pipeline by Biogen Inc, 2022
Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
Obsessive-Compulsive Disorder - Pipeline by Cannabis Science Inc, 2022
Obsessive-Compulsive Disorder - Pipeline by Evecxia Therapeutics Inc, 2022
Obsessive-Compulsive Disorder - Pipeline by Octapharma AG, 2022
Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, 2022
Obsessive-Compulsive Disorder - Pipeline by PharmaTher Holdings Ltd, 2022
Obsessive-Compulsive Disorder - Pipeline by Phytecs, 2022
Obsessive-Compulsive Disorder - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, 2022
Obsessive-Compulsive Disorder - Dormant Projects, 2022
Obsessive-Compulsive Disorder - Discontinued Products, 2022